Bjerregaard, A.-M., Nielsen, M., Hadrup, S. R., Szallasi, Z., & Eklund, A. C. (2017). MuPeXI: prediction of neo-epitopes from tumor sequencing data. Cancer Immunology, Immunotherapy, 66(9), 1123-1130.
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., . . . Holgado, E. (2015). Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. New England journal of medicine, 373(17), 1627-1639.
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E., Poddubskaya, E., . . . Holgado, E. (2015). Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. New England journal of medicine, 373(2), 123-135.
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., Van de Roemer, N., de Graaf, J., . . . Paret, C. (2012). Exploiting the mutanome for tumor vaccination. Cancer research, 72(5), 1081-1091.
Chen, F., Zou, Z., Du, J., Su, S., Shao, J., Meng, F., . . . Yang, Y. (2019). Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. The Journal of clinical investigation, 129(5), 2056-2070.
Cohen, C. J., Gartner, J. J., Horovitz-Fried, M., Shamalov, K., Trebska-McGowan, K., Bliskovsky, V. V., . . . Crystal, J. S. (2015). Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. The Journal of clinical investigation, 125(10), 3981-3991.
Ding, Z., Li, Q., Zhang, R., Xie, L., Shu, Y., Gao, S., . . . Wang, Y. (2021). Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal transduction and targeted therapy, 6(1), 1-12.
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., . . . Hubicki, A. M. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298(5594), 850-854.
Farhood, B., Najafi, M., & Mortezaee, K. (2019). CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. Journal of cellular physiology, 234(6), 8509-8521.
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., . . . Yates, B. (2018). CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature medicine, 24(1), 20.
Ghosh, S., & Chan, C.-K. K. (2016). Analysis of RNA-Seq data using TopHat and Cufflinks. Methods in molecular biology, 1374, 339-361.
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., . . . Roberts, I. M. (2016). Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nature medicine, 22(4), 433-438.
Gros, A., Tran, E., Parkhurst, M. R., Ilyas, S., Pasetto, A., Groh, E. M., . . . Fajardo, C. A. (2019). Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. The Journal of clinical investigation, 129(11), 4992-5004.
Guibert, N., & Mazières, J. (2015). Nivolumab for treating non-small cell lung cancer. Expert opinion on biological therapy, 15(12), 1789-1797.
Inogés, S., Tejada, S., de Cerio, A. L.-D., Pérez-Larraya, J. G., Espinós, J., Idoate, M. A., . . . Bendandi, M. (2017). A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. Journal of translational medicine, 15(1), 1-12.
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., . . . Zhou, C. (2019). Tumor neoantigens: from basic research to clinical applications. Journal of hematology & oncology, 12(1), 1-13.
Kilic, A., Landreneau, R. J., Luketich, J. D., Pennathur, A., & Schuchert, M. J. (2011). Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. Journal of Surgical Research, 167(2), 207-210.
Kim, B., Won, D., Jang, M., Kim, H., Choi, J. R., Kim, T. I., & Lee, S.-T. (2019). Next-generation sequencing with comprehensive bioinformatics analysis facilitates somatic mosaic APC gene mutation detection in patients with familial adenomatous polyposis. BMC medical genomics, 12(1), 1-7.
Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017). Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell metabolism, 26(1), 94-109.
Krishna, S., Lowery, F. J., Copeland, A. R., Bahadiroglu, E., Mukherjee, R., Jia, L., . . . Rosenberg, S. A. (2020). Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science, 370(6522), 1328-1334. doi:10.1126/science.abb9847
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., . . . Roberts, S. A. (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499(7457), 214-218.
Li, H., & Durbin, R. (2009). Fast and accurate short read alignment with Burrows–Wheeler transform. bioinformatics, 25(14), 1754-1760.
Lilleby, W., Gaudernack, G., Brunsvig, P. F., Vlatkovic, L., Schulz, M., Mills, K., . . . Inderberg, E. M. (2017). Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunology, Immunotherapy, 66(7), 891-901.
Lim, W. A., & June, C. H. (2017). The principles of engineering immune cells to treat cancer. Cell, 168(4), 724-740.
Network, C. G. A. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487(7407), 330.
Ozawa, Y., Amano, Y., Kanata, K., Hasegwa, H., Matsui, T., Kakutani, T., . . . Yokomura, K. (2019). Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. Medical Oncology, 36(4), 1-6.
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., . . . Cuffe, S. (2016). Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N engl J med, 375, 1823-1833.
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., . . . Dols, M. C. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, 389(10066), 255-265.
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., . . . Tycksen, E. (2013). Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature medicine, 19(6), 747.
Roney, K. (2019). Bone Marrow-Derived Dendritic Cells. Methods Mol Biol, 1960, 57-62. doi:10.1007/978-1-4939-9167-9_4
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., . . . Schrörs, B. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 547(7662), 222-226.
Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69-74.
Seebacher, N., Stacy, A., Porter, G., & Merlot, A. (2019). Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental & Clinical Cancer Research, 38(1), 1-39.
Seliktar-Ofir, S., Merhavi-Shoham, E., Itzhaki, O., Yunger, S., Markel, G., Schachter, J., & Besser, M. J. (2017). Selection of shared and neoantigen-reactive T cells for adoptive cell therapy based on CD137 separation. Frontiers in immunology, 8, 1211.
Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: a cancer journal for clinicians, 66(1), 7-30.
Siegel, R. L., Miller, K. D., Jemal, A., & Fuchs, H. E. (2021). Cancer Statistics, 2021. CA: a cancer journal for clinicians, 71(1), 7-33.
Small, E. J., Lance, R. S., Gardner, T. A., Karsh, L. I., Fong, L., McCoy, C., . . . Chang, N. (2015). A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 21(17), 3862-3869.
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., . . . Kurata, T. (2018). Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. New England journal of medicine, 378(2), 113-125.
Suresh, K., Naidoo, J., Lin, C. T., & Danoff, S. (2018). Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest, 154(6), 1416-1423.
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., . . . Groh, E. M. (2016). T-cell transfer therapy targeting mutant KRAS in cancer. New England journal of medicine, 375(23), 2255-2262.
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., . . . Hinrichs, C. S. (2014). Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science, 344(6184), 641-645.
Wolfl, M., Kuball, J., Ho, W. Y., Nguyen, H., Manley, T. J., Bleakley, M., & Greenberg, P. D. (2007). Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood, The Journal of the American Society of Hematology, 110(1), 201-210.
Yin, Q., Tang, J., & Zhu, X. (2019). Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer. Briefings in functional genomics, 18(2), 119-128.
Zeng, Y., Zhang, W., Li, Z., Zheng, Y., Wang, Y., Chen, G., . . . Cai, Z. (2020). Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report. Journal for immunotherapy of cancer, 8(1).